Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)
Scope of the report
The report titled “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)“ provide an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report analyzes the various causes and symptoms related to the prevalence of MS in patients. Further, the report analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Also, the domestic market of United States which is the largest contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major players like Teva, Biogen Idec, Merck KGaA, Bayer and Novartis.
Geographical Coverage
The global Multiple Sclerosis market is undergoing drastic change since the last few years. The rising diagnosis and treatment rate coupled with growing investment in research and development has played a key role in the determining the growth dynamics of the global Multiple Sclerosis (MS) market.
Currently, MS is known to affect an estimated 2.5 million people around the world with around 5000 new cases emerging each year. Since there is no particular cure or treatment for multiple sclerosis, the market is currently dominated by few drugs and medication like Copaxone, Avonex, Betaseron and Extavia which delay or reduce the progression of multiple sclerosis in individuals.
Until the last year, MS market was led by self injectables drugs such as Capaxone and Avonex that caused side effects like swelling, anxiety, redness and difficult breathing. To address these shortcomings and side effects, pharmaceutical companies developed oral drugs that are considered safe and effective. With the beginning of 2013, oral drugs such as Gilenya and Aubagio witnessed rapid demand due to their higher efficacy and better results. In addition, there are many drugs down the pipeline that would change the dynamics and growth of the multiple sclerosis market in future. For instance, Teva hopes its Copaxone successor, laquinimod, may help it preserve some market share when Copaxone loses patent protection.
The report titled “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)“ provide an insight into the market dynamics and various trends and opportunities associated with the global multiple sclerosis market. The report analyzes the various causes and symptoms related to the prevalence of MS in patients. Further, the report analyzes the global market sizing and growth of multiple sclerosis in terms of revenue, number of patients and sales of effective drugs. Also, the domestic market of United States which is the largest contributor to the global multiple sclerosis market has been assessed. The report concludes with a brief discussion of major factors driving the global multiple sclerosis market and profiles major players like Teva, Biogen Idec, Merck KGaA, Bayer and Novartis.
Geographical Coverage
- Global
- United States
- Teva
- Biogen Idec
- Merck KGaA
- Bayer
- Novartis
The global Multiple Sclerosis market is undergoing drastic change since the last few years. The rising diagnosis and treatment rate coupled with growing investment in research and development has played a key role in the determining the growth dynamics of the global Multiple Sclerosis (MS) market.
Currently, MS is known to affect an estimated 2.5 million people around the world with around 5000 new cases emerging each year. Since there is no particular cure or treatment for multiple sclerosis, the market is currently dominated by few drugs and medication like Copaxone, Avonex, Betaseron and Extavia which delay or reduce the progression of multiple sclerosis in individuals.
Until the last year, MS market was led by self injectables drugs such as Capaxone and Avonex that caused side effects like swelling, anxiety, redness and difficult breathing. To address these shortcomings and side effects, pharmaceutical companies developed oral drugs that are considered safe and effective. With the beginning of 2013, oral drugs such as Gilenya and Aubagio witnessed rapid demand due to their higher efficacy and better results. In addition, there are many drugs down the pipeline that would change the dynamics and growth of the multiple sclerosis market in future. For instance, Teva hopes its Copaxone successor, laquinimod, may help it preserve some market share when Copaxone loses patent protection.
1. EXECUTIVE SUMMARY
2. GLOBAL MULTIPLE SCLEROSIS MARKET: AN OVERVIEW
3. GLOBAL MULTIPLE SCLEROSIS MARKET: AN ANALYSIS
3.1. Global Multiple Sclerosis Market: Sizing & Growth (Actual & Forecast)
3.2. Number of Multiple Sclerosis Patients Worldwide
3.3. Global Multiple Sclerosis Market: Market Share Analysis
3.3.1. Market Share: By Major Players
3.3.2. United States Vs Rest of the World
3.3.3. Multiple Sclerosis Market: Competitors Share Shift
3.4. Average Revenue per Patient by Region
4. MULTIPLE SCLEROSIS MARKET: COUNTRY ANALYSIS
4.1. United States: Multiple Sclerosis Market
4.1.1. United States Multiple Sclerosis Market: Sizing and Growth (Actual & Forecast)
4.1.2. Number of MS Patients in the United States
5. GROWTH DRIVERS OF MULTIPLE SCLEROSIS MARKET
6. COMPANY PROFILES: MULTIPLE SCLEROSIS MARKET
6.1. Teva
6.1.1. Business Description
6.1.2. Financial Analysis
6.1.3. Business Strategies
6.2. Biogen Idec
6.2.1. Business Description
6.2.2. Financial Analysis
6.2.3. Business Strategies
6.3. Merck KGaA
6.3.1. Business Description
6.3.2. Financial Analysis
6.3.3. Business Strategies
6.4. Bayer
6.4.1. Business Description
6.4.2. Financial Analysis
6.4.3. Business Strategies
6.5. Novartis
6.5.1. Business Description
6.5.2. Financial Analysis
6.5.3. Business Strategies
2. GLOBAL MULTIPLE SCLEROSIS MARKET: AN OVERVIEW
3. GLOBAL MULTIPLE SCLEROSIS MARKET: AN ANALYSIS
3.1. Global Multiple Sclerosis Market: Sizing & Growth (Actual & Forecast)
3.2. Number of Multiple Sclerosis Patients Worldwide
3.3. Global Multiple Sclerosis Market: Market Share Analysis
3.3.1. Market Share: By Major Players
3.3.2. United States Vs Rest of the World
3.3.3. Multiple Sclerosis Market: Competitors Share Shift
3.4. Average Revenue per Patient by Region
4. MULTIPLE SCLEROSIS MARKET: COUNTRY ANALYSIS
4.1. United States: Multiple Sclerosis Market
4.1.1. United States Multiple Sclerosis Market: Sizing and Growth (Actual & Forecast)
4.1.2. Number of MS Patients in the United States
5. GROWTH DRIVERS OF MULTIPLE SCLEROSIS MARKET
6. COMPANY PROFILES: MULTIPLE SCLEROSIS MARKET
6.1. Teva
6.1.1. Business Description
6.1.2. Financial Analysis
6.1.3. Business Strategies
6.2. Biogen Idec
6.2.1. Business Description
6.2.2. Financial Analysis
6.2.3. Business Strategies
6.3. Merck KGaA
6.3.1. Business Description
6.3.2. Financial Analysis
6.3.3. Business Strategies
6.4. Bayer
6.4.1. Business Description
6.4.2. Financial Analysis
6.4.3. Business Strategies
6.5. Novartis
6.5.1. Business Description
6.5.2. Financial Analysis
6.5.3. Business Strategies
LIST OF FIGURES
Figure 1: Multiple Sclerosis Diagrammatic Overview
Figure 2: Global Multiple Sclerosis Market Size, 2007-12 (US$ Million)
Figure 3: Global Multiple Sclerosis Market Size Forecast, 2013-18 (US$ Million)
Figure 4: Global Multiple Sclerosis Patients, 2007-12
Figure 5: Global Multiple Sclerosis Patients Forecast, 2013-18
Figure 6: Global Multiple Sclerosis Market, By Major Players, By Value (2012)
Figure 7: Global Multiple Sclerosis Market Share Analysis, By Geography, 2007-12
Figure 8: Global Multiple Sclerosis Competitor Share shift, 2013-16
Figure 9: Average Revenue per Patient, By Region, 2007-2012 (US$ Thousands)
Figure 10: United states Multiple Sclerosis Market, 2007-12 (US$ Million)
Figure 11: United states Multiple Sclerosis Market Forecast, 2013-18 (US$ Million)
Figure 12: United States Multiple Sclerosis Patients, 2007-12
Figure 13: United States Multiple Sclerosis Patients Forecast, 2013-18
Figure 14: Number of Multiple Sclerosis Patients Worldwide, 2010-2016E
Figure 15: Global Healthcare Expenditure, 2007-2012 (US$ Trillion)
Figure 16: Copaxone Sales, By Region, FY’2011-FY’13
Figure 17: Biogen Idec Global Sales, 2008-2012 (US$ Million)
Figure 18: Global Rebif Sales, 2008-2012 (US$ Million)
Figure 19: Merck Rebif Sales, By Region (2012)
Figure 20: Global Betaseron Sales, 2008-2012 (US$ Million)
Figure 21: Bayer’s Pharmaceuticals Global Sales, By Region (2012)
Figure 22: Global Extavia Net Sales, 2008-2012 (US$ Million)
Table 1: Most Common Drugs used for Treating Multiple sclerosis
Table 2: Product Sales of Avonex & Tysabri, 2008-12 (US$ Million)
Figure 1: Multiple Sclerosis Diagrammatic Overview
Figure 2: Global Multiple Sclerosis Market Size, 2007-12 (US$ Million)
Figure 3: Global Multiple Sclerosis Market Size Forecast, 2013-18 (US$ Million)
Figure 4: Global Multiple Sclerosis Patients, 2007-12
Figure 5: Global Multiple Sclerosis Patients Forecast, 2013-18
Figure 6: Global Multiple Sclerosis Market, By Major Players, By Value (2012)
Figure 7: Global Multiple Sclerosis Market Share Analysis, By Geography, 2007-12
Figure 8: Global Multiple Sclerosis Competitor Share shift, 2013-16
Figure 9: Average Revenue per Patient, By Region, 2007-2012 (US$ Thousands)
Figure 10: United states Multiple Sclerosis Market, 2007-12 (US$ Million)
Figure 11: United states Multiple Sclerosis Market Forecast, 2013-18 (US$ Million)
Figure 12: United States Multiple Sclerosis Patients, 2007-12
Figure 13: United States Multiple Sclerosis Patients Forecast, 2013-18
Figure 14: Number of Multiple Sclerosis Patients Worldwide, 2010-2016E
Figure 15: Global Healthcare Expenditure, 2007-2012 (US$ Trillion)
Figure 16: Copaxone Sales, By Region, FY’2011-FY’13
Figure 17: Biogen Idec Global Sales, 2008-2012 (US$ Million)
Figure 18: Global Rebif Sales, 2008-2012 (US$ Million)
Figure 19: Merck Rebif Sales, By Region (2012)
Figure 20: Global Betaseron Sales, 2008-2012 (US$ Million)
Figure 21: Bayer’s Pharmaceuticals Global Sales, By Region (2012)
Figure 22: Global Extavia Net Sales, 2008-2012 (US$ Million)
Table 1: Most Common Drugs used for Treating Multiple sclerosis
Table 2: Product Sales of Avonex & Tysabri, 2008-12 (US$ Million)
